• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?估算泰国人对质量调整生命年的支付意愿:健康改善的背景是否重要?
Clinicoecon Outcomes Res. 2013;5:29-36. doi: 10.2147/CEOR.S38062. Epub 2013 Jan 9.
2
Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.社区成员和患者对与带状疱疹相关的临时健康状态的偏好为基础的 QALY 的支付意愿。
Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.
3
Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.泰国为挽救生命的治疗所支付的每质量调整生命年的意愿。
BMJ Open. 2015 Oct 5;5(10):e008123. doi: 10.1136/bmjopen-2015-008123.
4
An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.一项关于估计伊朗西部挽救生命治疗的成本效益阈值的探索性研究。
Cost Eff Resour Alloc. 2020 Oct 23;18:47. doi: 10.1186/s12962-020-00241-9. eCollection 2020.
5
Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.对基础胰岛素相关属性改善的偏好:瑞典糖尿病和非糖尿病患者群体的时间权衡与支付意愿调查
J Med Econ. 2016 Oct;19(10):945-58. doi: 10.1080/13696998.2016.1187152. Epub 2016 May 31.
6
Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia.探索马来西亚槟城州居民为质量调整生命年支付费用的意愿。
Clinicoecon Outcomes Res. 2014 Oct 23;6:473-81. doi: 10.2147/CEOR.S67375. eCollection 2014.
7
Willingness to pay for a quality-adjusted life-year: the individual perspective.对质量调整生命年的支付意愿:个体视角。
Value Health. 2010 Dec;13(8):1046-55. doi: 10.1111/j.1524-4733.2010.00781.x. Epub 2010 Sep 3.
8
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?对获取每质量调整生命年支付意愿的研究进行的系统评价:这是否能证明成本效益阈值的合理性?
PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.
9
Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP).心血管疾病患者质量调整生命年(QALY)的货币价值:一项支付意愿研究(WTP)
Iran J Pharm Res. 2017 Spring;16(2):823-833.
10
Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.肿瘤学中治愈性疗法价值的评估:一项在中国的支付意愿研究。
Cost Eff Resour Alloc. 2023 Jun 5;21(1):37. doi: 10.1186/s12962-023-00442-y.

引用本文的文献

1
Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand.肾去神经术治疗高血压:来自中国内地、日本和泰国的跨国成本效益分析见解
Health Econ Rev. 2025 Aug 13;15(1):69. doi: 10.1186/s13561-025-00669-w.
2
Cost-utility analysis of botulinum toxin type A versus oral drug treatment in patients with severe blepharospasm in Thailand.泰国严重眼睑痉挛患者中A型肉毒杆菌毒素与口服药物治疗的成本效益分析
PLoS One. 2025 Apr 21;20(4):e0319926. doi: 10.1371/journal.pone.0319926. eCollection 2025.
3
Economic evaluation of tenofovir disoproxil fumarate prophylaxis to prevent mother-to-child transmission of Hepatitis B virus infection: evidence from a lower-middle income country.替诺福韦酯预防乙型肝炎病毒母婴传播的经济学评价:来自中低收入国家的证据
BMC Health Serv Res. 2024 Dec 28;24(1):1658. doi: 10.1186/s12913-024-12152-z.
4
Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid-Lowering Therapy: A Multinational Economic Evaluation Study.降脂治疗的心血管疾病患者最佳药物依从性的预期成本节约:一项多国经济评估研究。
J Am Heart Assoc. 2024 Nov 19;13(22):e037792. doi: 10.1161/JAHA.124.037792. Epub 2024 Nov 15.
5
Economic evaluation of diagnosis and treatment for latent tuberculosis infection among contacts of pulmonary tuberculosis patients in Thailand.泰国肺结核患者接触者潜伏性结核感染诊断和治疗的经济评价。
Sci Rep. 2024 Jul 31;14(1):17693. doi: 10.1038/s41598-024-68452-1.
6
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.医疗保健公共政策中使用成本效益阈值:进展与挑战。
Appl Health Econ Health Policy. 2024 Nov;22(6):797-804. doi: 10.1007/s40258-024-00900-5. Epub 2024 Jul 12.
7
A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.一项关于直接 elicitation 需求方成本效益阈值的系统评价:对低收入和中等收入国家的启示。
PLoS One. 2024 Feb 8;19(2):e0297450. doi: 10.1371/journal.pone.0297450. eCollection 2024.
8
Cost-utility analysis of sutureless and rapid deployment versus conventional aortic valve replacement in patients with moderate to severe aortic stenosis in Thailand.泰国中重度主动脉瓣狭窄患者中无缝合快速部署与传统主动脉瓣置换的成本效用分析。
PLoS One. 2024 Jan 19;19(1):e0296875. doi: 10.1371/journal.pone.0296875. eCollection 2024.
9
Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值:一项关于健康生活年支付意愿的社区调查。
BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.
10
Health-related quality of life and willingness to pay measurement among patients on warfarin in Thailand.泰国华法林治疗患者的健康相关生活质量及支付意愿测量
J Pharm Policy Pract. 2023 Oct 30;16(1):130. doi: 10.1186/s40545-023-00632-2.

本文引用的文献

1
Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis.每质量调整生命年的支付意愿:一个阈值是否足以用于决策?:一项慢性前列腺炎患者研究的结果。
Med Care. 2011 Mar;49(3):267-72. doi: 10.1097/MLR.0b013e31820192cd.
2
The social value of a QALY: raising the bar or barring the raise?QALY 的社会价值:提高标准还是禁止提高?
BMC Health Serv Res. 2011 Jan 11;11:8. doi: 10.1186/1472-6963-11-8.
3
Willingness to pay for a quality-adjusted life-year: the individual perspective.对质量调整生命年的支付意愿:个体视角。
Value Health. 2010 Dec;13(8):1046-55. doi: 10.1111/j.1524-4733.2010.00781.x. Epub 2010 Sep 3.
4
Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.在亚太地区,医疗保健系统迅速变化,需要进行循证决策:泰国、韩国和中国台湾。
Value Health. 2009 Nov-Dec;12 Suppl 3:S4-11. doi: 10.1111/j.1524-4733.2009.00620.x.
5
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.评估医疗保健中的成本效益:50,000 美元/QALY 阈值的历史。
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78. doi: 10.1586/14737167.8.2.165.
6
Willingness to pay for a QALY: past, present and future.对 QALY 的支付意愿:过去、现在和未来。
Expert Rev Pharmacoecon Outcomes Res. 2008 Dec;8(6):575-82. doi: 10.1586/14737167.8.6.575.
7
Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.与 A 组链球菌疾病和疫苗接种相关的健康结果偏好。
Health Qual Life Outcomes. 2010 Mar 12;8:28. doi: 10.1186/1477-7525-8-28.
8
Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.社区成员和患者对与带状疱疹相关的临时健康状态的偏好为基础的 QALY 的支付意愿。
Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.
9
Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?运用药物经济学进行政策制定:通过应用成本效益阈值能否增强理性决策?
Expert Rev Pharmacoecon Outcomes Res. 2004 Jun;4(3):247-50. doi: 10.1586/14737167.4.3.247.
10
International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?国际意愿支付(WTP)额外获得一个 QALY 的调查:成本效益的阈值是多少?
Health Econ. 2010 Apr;19(4):422-37. doi: 10.1002/hec.1481.

估算泰国人对质量调整生命年的支付意愿:健康改善的背景是否重要?

Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

作者信息

Thavorncharoensap Montarat, Teerawattananon Yot, Natanant Sirin, Kulpeng Wantanee, Yothasamut Jomkwan, Werayingyong Pitsaphun

机构信息

Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand ; Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand.

出版信息

Clinicoecon Outcomes Res. 2013;5:29-36. doi: 10.2147/CEOR.S38062. Epub 2013 Jan 9.

DOI:10.2147/CEOR.S38062
PMID:23345984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3548562/
Abstract

BACKGROUND

This study aims to elicit the value of the willingness to pay (WTP) for a quality-adjusted life year (QALY) and to examine the factors associated with the WTP for a QALY (WTP/QALY) value under the Thai health care setting.

METHODS

A community-based survey was conducted among 1191 randomly selected respondents. Each respondent was interviewed face-to-face to elicit his/her health state preference in each of three pairs of health conditions: (1) unilateral and bilateral blindness, (2) paraplegia and quadriplegia, and (3) mild and moderate allergies. A visual analog scale (VAS) and time trade off (TTO) were used as the eliciting methods. Subsequently, the respondents were asked about their WTP for the treatment and prevention of each pair of health conditions by using a bidding-game technique.

RESULTS

With regards to treatment, the mean WTP for a QALY value (WTP/QALY(treatment)) estimated by the TTO method ranged from 59,000 to 285,000 baht (16.49 baht = US$1 purchasing power parity [PPP]). In contrast, the mean WTP for a QALY value in terms of prevention (WTP/QALY(prevention)) was significantly lower, ranging from 26,000 to 137,000 baht. Gender, household income, and hypothetical scenarios were also significant factors associated with the WTP/QALY values.

CONCLUSION

The WTP/QALY values elicited in this study were approximately 0.4 to 2 times Thailand's 2008 GDP per capita. These values were in line with previous studies conducted in several different settings. This study's findings clearly support the opinion that a single ceiling threshold should not be used for the resource allocation of all types of interventions.

摘要

背景

本研究旨在得出质量调整生命年(QALY)的支付意愿(WTP)值,并考察泰国医疗保健环境下与QALY支付意愿(WTP/QALY)值相关的因素。

方法

对1191名随机抽取的受访者进行了一项基于社区的调查。每位受访者都接受了面对面访谈,以了解其在三对健康状况中的每一对中的健康状态偏好:(1)单眼失明和双眼失明,(2)截瘫和四肢瘫,以及(3)轻度和中度过敏。采用视觉模拟量表(VAS)和时间权衡法(TTO)作为获取偏好的方法。随后,通过投标博弈技术询问受访者对每对健康状况的治疗和预防的支付意愿。

结果

在治疗方面,通过TTO方法估计的QALY值的平均支付意愿(WTP/QALY(治疗))范围为59,000至285,000泰铢(16.49泰铢 = 1美元购买力平价[PPP])。相比之下,预防方面的QALY值的平均支付意愿(WTP/QALY(预防))显著较低,范围为26,000至137,000泰铢。性别、家庭收入和假设情景也是与WTP/QALY值相关的重要因素。

结论

本研究得出的WTP/QALY值约为泰国2008年人均国内生产总值的0.4至2倍。这些值与先前在几个不同环境中进行的研究一致。本研究的结果明确支持以下观点,即不应将单一的上限阈值用于所有类型干预措施的资源分配。